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Drug delivery systemsAbstract Conjugation of cholesterol moiety to active compounds for either cancer treatment or
diagnosis is an attractive approach. Cholesterol derivatives are widely studied as cancer diagnostic
agents and as anticancer derivatives either in vitro or in vivo using animal models. In largely grow-
ing studies, anticancer agents have been chemically conjugated to cholesterol molecules, to enhance
their pharmacokinetic behavior, cellular uptake, target speciﬁcity, and safety. To efﬁciently deliver
anticancer agents to the target cells and tissues, many different cholesterol–anticancer conjugates
were synthesized and characterized, and their anticancer efﬁciencies were tested in vitro and in vivo.
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According to the cancer incidence and survival report 2007 by
the Saudi cancer registry (scr.org.sa), 12,309 cancer cases were
diagnosed in Saudi Arabia in 2007 (Saudi Arabia’s population
at that time was approximately 17 million). Breast cancer
ranked ﬁrst in incidence (13.8%), followed by colorectal
(9.9%), non-Hodgkin lymphoma (NHL) (7.7%), thyroid
(6.4%), leukemia (6.2%), liver (4.8%), and lung cancer
(4.5%). The top ﬁve cancers in females were breast, thyroid,
colorectal, NHL, and leukemia; in males, the top ﬁve cancers
were colorectal, NHL, leukemia, lung, and liver. Moreover,
cancer is the second most common cause of death in the US,
exceeded only by heart disease, accounting for nearly 1 of
every 4 deaths (American Cancer Society, 2012).
Cholesterol is a neutral lipid that plays an essential role in
the maintenance of the integrity of biologic membranes and
serves as a precursor in the synthesis of many endocrine medi-
ators. It is also synthesized in mammalian cells via the mevalo-
nate pathway. Recent clinical has demonstrated a possible
linkage of cholesterol to prostatic cancer and benign prostatic
hyperplasia. Accumulation of cholesterol within the lipid raft
component of the cellular plasma membrane may stimulate
signaling pathways that promote prostate tumor growth and
progression. In addition, cholesterol-lowering drugs, such as
statins, have exhibited some promising results for these pros-
tatic diseases (Yat-Ching, 2011). Herein, we shed light upon
the anticancer activity of various cholesterol conjugates that
have been published in the literatures.
2. The biological properties of cholesterol
Distribution of cholesterol in human organs and tissues varies
(Fig. 1) (Alanazi et al., 2003). Cholesterol serves many biolog-
ical functions. Depending on the cell types, cholesterol content
of cell membranes varies (Yeagle, 1988). The membranes of
most cells have an intermediate cholesterol/phospholipid ratioFigure 1 Distribution of cholesterol in human organs and
tissues.and possess both protective and metabolite-transport func-
tions. Cell membranes with a high cholesterol ratio, such as
those in the epidermis layer of the skin, have high stability
and relatively low permeability, reﬂecting their major function-
ality as a protective barrier (Yeagle, 1988; Proksch, 1990).
Membranes of the intracellular organelles, such as mitochon-
dria, have a low cholesterol ratio and, thus, are ﬂuidic and per-
meable (Yeagle, 1988). The total amount of cholesterol bound
to lipoproteins in blood circulation is normally about 150–
200 mg per 100 ml of serum. The body obtains cholesterol
from two routes, either from dietary sources or from de novo
biosynthesis.
Various lipoproteins act as primary carriers in cholesterol
transport through blood circulation. Dietary cholesterol is
transported from the intestine to the liver in large lipoprotein
particles. The liver secretes very low density lipoproteins
(VLDL), containing cholesterol and is partially converted into
low density lipoprotein (LDL) through the action of lipoprotein
lipase. LDL carries cholesterol from the liver to body tissues
while high density lipoprotein (HDL) transports cholesterol
from various tissues back to the liver (Alanazi et al., 2003).
Cholesterol is the sole precursor to all steroid hormones.
These steroids include glucocorticoids responsible for blood
sugar regulation, mineralcorticoids that regulate mineral bal-
ance and blood pressure and sex hormones responsible for
many functions. Cholesterol is the precursor to a hormone
called pregnenolone, which has not only its own functions
but also be the precursor to all other steroid hormones. Preg-
nenolone is converted into progesterone, a sex hormone, which
in turn is converted into cortisol, which regulates inﬂammation
and blood sugar, aldosterone, which regulates mineral balance
and blood pressure, or testosterone, a type of sex hormone re-
ferred to as an androgen, which regulates libido, muscle mass,
and plays other roles. In females, and to a lesser degree in
males, testosterone is further modiﬁed, undergoing conversion
to estradiol, a different type of sex hormone called an estrogen
(Hume and Boyd, 1978). Many neurotransmitter receptors are
created with cholesterol, and maintained with the aid of cho-
lesterol (Fantini and Barrantes, 2009; Baier and Barrantes,
2007; Barrantes, 2010). Our nerve cells require cholesterol to
function and maintain ﬂuidity (Barres and Smith, 2001). The
central nervous system (CNS) comprises the highest concentra-
tion of cholesterol in the body, over any other organ (Dietschy
and Turley, 2004). For the in vivo synthesis of Vitamin D from
the Sun, cholesterol is needed (Bouillon et al., 1995). Bile salts
are amphipathic derivatives of cholesterol, and are needed to
emulsify dietary fats so they can be digested properly (Dennis-
ton et al., 2007).3. Serum cholesterol and cancer risk
For males with low serum cholesterol levels it has been noted
that about 30% increased risk of cancer is expected. For
Figure 2 LDL particle.
Targeting cancer using cholesterol conjugates 5females, some studies examined suggest no more than a 5–10%
increased risk associated with having low serum cholesterol
(Kritchevsky, 1992). The cancers most consistently associated
with low serum cholesterol levels are those of the colon and
the lung in males, the cervix and the breast (but only for fe-
males under 50 years of age) in females, and leukemia in both
sexes. In contrast, high cholesterol levels have been linked with
an increase in brain cancer. While immunologic, genetic, and
dietary explanations have been offered to explain the associa-
tion, it is difﬁcult to support the idea that low serum choles-
terol causes cancer in any direct manner. In China, counties
with the lowest average plasma cholesterol levels have the low-
est cancer rates (Peto et al., 1989). While this observation is
open to a number of interpretations, it does not support the
idea that low serum cholesterol is a tumor initiator. On the
other hand, late stage of cancer usually is accompanied by a
low level of cholesterol due to the high growth rate of the can-
cer cells.
4. Rationale for using cholesterol-based conjugates for cancer
Lipoproteins are macromolecules that transport lipids through
the blood to various cell types, where they undergo receptor-
mediated uptake. Based on densities there are 5 classes of lipo-
protein including chylomicrons, very low density lipoproteins
(VLDL), intermediate density lipoproteins (IDL), low-density
lipoproteins (LDL), and high-density lipoproteins (HDL).
Chylomicrons are the largest lipoproteins and they are synthe-
sized in the intestinal tract. Their main function is the trans-
port of dietary triglycerides and cholesterol. Very low density
lipoproteins (VLDL) are synthesized in the liver and function
to export triglycerides to peripheral tissues. LDL is the major
vehicle to transport cholesteryl esters to peripheral cells.
LDL contains one major apolipoprotein (i.e. apo B-100),
which allows LDL to bind to the LDL receptors on the periph-
eral cell surfaces and to be internalized by these cells through a
receptor mediated endocytosis. High-density lipoproteins
(HDL) are the smallest lipoprotein due to high protein/lipid
ratio. HDL works as a lipid scavenger, transporting choles-
terol from various tissues back to the liver (Fars, 2003).
Cholesterol conjugation approach is widely used in delivery
of the anticancer agents to tumor tissues selectively. This ap-
proach includes physical or biological targeting strategy [5].
Physical targeting is based on the increase of the lipophilicity
of the anticancer compounds that helps the intracerebral deliv-
ery of anticancer agents to brain tumor [6]. Cholesterol based
boron anticancer conjugate (cholesteryl 1,12-dicarba-closo-
dodecaborane 1-carboxylate, BCH) showed a rapid distribu-
tion from the site of intracerebral injection in tumor-bearing
rat (Alanazi et al., 2004). However, biological targeting can
be based on two facts. The ﬁrst one is the difference in the sub-
strate uptake among different human organs. Basically, choles-
terol accumulates in the ovarian tissue and is used to
synthesize sex hormones. Therefore, cholesteryl drug conju-
gates could also be used for drug targeting to the ovary. Ades
et al. (2001) showed that injection of labeled cholesteryl oleate
in patients bearing ovarian tumors resulted in a eightfold up-
take by the malignant tumors compared to the contralateral
normal ones [93]. The second fact is the difference in the sub-
strate uptake between cancer cells and normal cells. In other
words, due to the high growth rate of cancerous cells, they re-
quire more nutrients and various receptors, thus, are overexpressed, such as folate receptors [12], transferrin receptors
[14], growth factor receptors [15], and low-density lipoprotein
receptors [18]. Drug delivery systems linked to ligands that tar-
get these receptors have been investigated [14], [32].
The high requirement for LDL by malignant cells and thus
the overexpression of LDL receptors can be utilized for devel-
oping a novel targeted drug delivery system. Because the
amount of new membrane synthesized in rapidly growing can-
cer cells is considerable, they consume large amounts of choles-
terol. The LDL receptors (LDL is the major component of the
cholesterol-transport pathway) are much more active on many
types of cancer cells than on the corresponding normal cells
(Rudling et al., 1990, Maletinska et al., 2000). Thus, many
types of tumor cells display a higher level of receptor mediated
LDL uptakes compared to corresponding normal tissues. The
increase in LDL receptor activity in cancer cells is suggested to
be due to high cholesterol demand for cell growth and/or a
mechanism directly linked to cell transformation (Favre,
1992). LDL has therefore been proposed as a potential carrier
for chemotherapeutic agents (Vitols, 1991). There are three
main strategies to utilize LDL as a drug delivery system. First,
LDL has been utilized as a targeting vector for cancer therapy
through loading drugs into LDL particles and subsequent
administration of the preloaded LDL. This strategy (preload-
ing drug into LDL) suffers from several limitations, such as
being tedious, the possibility of losing LDL targeting capabil-
ity (due to modiﬁcation of apo B100 in the presence of such
harsh conditions), and risk of cross contamination (i.e. it is a
biohazard blood product). A second strategy is developing
LDL resembling delivery systems, which follow a similar met-
abolic pathway to that of natural LDL. This strategy involved
using a drug delivery system such as protein free nanoemulsion
(Shawer et al., 2002; Fars, 2003) and Apolipoprotein B built-in
phospholipid cholesterol liposomes (Klimov et al., 1983). The
third strategy, which is a combination of the two previous pio-
neer strategies, is based on targeting the LDL particle in vivo
and allowing the anticancer agent to be transferred to the nat-
ural LDL inside of the body. Basically, LDL will function as a
secondary carrier of anticancer molecules in vivo and deliver
these molecules selectively toward cancerous cells via elevated
LDL receptor. This approach required anticancer molecules to
have afﬁnity to the LDL particle endogenously and to have
certain special physicochemical properties (Fars, 2003). The
fourth strategy is the developing LDL-conjugated anti-cancer
drug as a new drug delivery system for cancer therapy. This
Figure 3 LDL pathway for anticancer-targeted delivery; administration of cholesterol conjugate (a); diffusion of cholesterol conjugate
into LDL (b); LDL-cholesterol conjugate binds with LDL-receptor (c); receptor-mediated endocytosis of LDL-particles (d); Releasing of
cholesterol conjugate in cytoplasm.
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rier of cholesterol. The majority of cholesterol is obtained
through the LDL receptor-mediated endocytosis mostly in
the form of cholesterol ester. Fig. 2 shows that LDL particle
is a lipid core, of triglycerides (20%) and cholesteryl esters
(80%), that is covered by a monolayer of phospholipid. Basi-
cally, only lipophilic drug species partition into the core of
the LDL system. Since cholesterol (in its ester form) is the na-
tive component of LDL, conjugation of an antitumor moiety
with cholesterol facilitates the loading of these compounds into
LDL. Synthesizing antitumor conjugates that mimic native
cholesteryl esters in its chemical and physical characteristics
may result in effectively transferring these compounds into
LDL (Fars, 2003). The proposed scenario of targeting these
compounds to cancer cells is presented in Fig. 3. Following
the administration of cholesterol–antitumor conjugates these
compounds will partition into LDL particles in the physiolog-
ical environment and, thus, utilize the elevated LDL receptor
expression on tumor cells and enter the tumor cells via receptor
mediated endocytosis. Degradation of LDL particles by endo-
somal enzymes will result in the liberation of antitumor mole-
cules which act as tumoricides.
5. Cholesterol-based conjugates for cancer disease diagnosis
The diagnoses of cancer diseases in its early stage play a major
role in decreasing the risk of associated complications. Choles-
terol has been conjugated with imaging molecules for the
detection of manifestations associated with adrenal glands
and liver disease. Several cholesteryl conjugates (Fig. 4) are re-
ported for human adrenal imaging which were gamma emit-
ting agent 131I-19-iodocholesterol (NM-145, 1) (Liebermann
et al., 1971), 6b-131I iodomethyl-19-norcholest-5-(10)-en-3b-ol
(NP-59, 2) (Gross et al., 1994), 37Se-selenomethyl-norcholes-
terol (Scintadren, 3) (Hawkins et al., 1980) and cholesteryl-p-
[18F]ﬂuorobenzoate ([18F] CFB, 4) (Johnson and Welch,
1999) that has used for distinguishing between adrenal produc-
ing adenoma (APA) and bilateral adrenal hyperplasia (BHA)
(Gums and Wilt, 1997). As the liver plays an important role
in lipid metabolism, linking an imaging agent to cholesterol
in cholesteryl iopanoate (5) facilitates the radioimaging agentto be taken up by the liver as a potential imaging agent in he-
patic adenocarcinoma CT (Longino et al., 1984).
5.1. Cholesterol analogs as anticancer
Many steroids and their triterpene precursors (Fig. 5) (Mihai
et al., 2011) such as betulinic, oleanolic, and ursolic acids
and stigmasterol have been reported as antitumor agents
(Awad and Fink, 2000; Ma et al., 2005). Moreover, many pre-
vious studies have shown that some phytocomponents related
to cholesterol presented induced apoptosis (Itoh et al., 2008).
However, most of the steroids presented in the literature as
cytotoxic compounds are polyhydroxylated or contain a a,b-
unsaturated ketone function (Amagata et al., 1999; Wang
et al., 2006; Samadi et al., 2010; Shang et al., 2011). Besides,
these terpenoids caused cell death when they are presented as
sulfate (Zhang et al., 2007) or quaternary ammonium salts
(Brassart et al., 2007).
6. Prostate cancer
It has long been established that prostatic growth is stimulated
by 5a-dihydrotestosterone (DHT), rather than by the classic
testicular hormone testosterone (T) (Bruchovsky and Wilson,
1968). Metabolically DHT is made from T by the action of
the enzyme steroid 5a-reductase (5AR). A deﬁciency of 5AR
in males results in an incomplete differentiation of external
genitalia at birth (Abul-Hajj, 1972). On the other hand, abnor-
mally high 5AR activity in humans results in excessively high
DHT levels in peripheral tissues, which is implicated in the
pathogenesis of prostate cancer, benign prostatic hyperplasia
(BPH), acne and male pattern baldness (Andersson et al.,
1989; Cabeza et al., 2004). Two distinct isozymes of 5AR are
differentially expressed in human tissues and referred to as
type 1 5AR (5AR1) and type 2 5AR (5AR2) (Andersson and
Russell, 1990; Thigpen et al., 1993; Russell and Wilson,
1994). Although 5AR1 is predominantly expressed in the skin
and the liver, 5AR2 is mainly expressed in prostate, seminal
vesicles, liver and epididymis (Hartmann et al., 2000).
Various steroidal (Ramı´rez et al., 2002; Flores et al., 2003)
and non-steroidal (Audia et al., 1993; Jones et al., 1993; Kurup
Figure 4 Compounds 1–5.
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steroid 5a-reductase enzyme (5AR). Of these, ﬁnasteride (24)
(PROSCAR, Fig. 6), a type II-selective 5a-reductase inhibi-
tor, was the ﬁrst 5AR inhibitor approved in the USA for the
treatment of BPH and prostate cancer. It has also been demon-
strated that dutasteride (25) (Fig. 6) acts as a type 1 5AR
(5AR1) and type 2 5AR (5AR2) inhibitor (Lazier et al.,
2004) and turosteride (26) (Fig. 6) is selective for the type II
isoform of 5a-reductase. However, since ﬁnasteride is slow act-
ing and produces side effects affecting sexual function (Sud-
duth and Koronkowski, 1993), this has caused us and others
to seek new classes of steroidal and non-steroidal inhibitors.
A series of C21 steroids (Fig. 7) showed less activity than
ﬁnasteride (IC50: 1.2 nM) as inhibitors against 5a-reductase
(Kim and Ma, 2009; Sujeong et al., 2012). Of these steroids
4-azasteroid-20-oximes (28, 30) showed good inhibitory activ-
ity (IC50: 26, 10 and 11 nM) and were more active than corre-
sponding 4-azasteroid 20-ones (27, 29) (IC50: 2300, 6100 nM).On the other hand, introduction of a double bond at 1-position
of these 4-azasteroides results in 4-azasteroid-20-oxime (32) of
good inhibitory activity (IC50: 11 nM) as well as its analog 4-
azasteroid-20-one (31) (IC50: 14 nM).
For some non azasteroid derivatives (Fig. 8), pregnenolone
(33) showed high inhibitory activity of 5a-reductase enzyme
(IC50: 6.5 nM) whereas its derivatives 3b-Acetoxypregneno-
lone (34) and 20-oxime derivative (35), 3b-hydroxy-5a,
6a-epoxypregnane and 20-oxime (36 and 37), 3b-hydroxy pregn-
4-ene-20-oxime (38) exhibited no inhibition for 5a-reductase
enzyme (IC50 > 10000 nM). This leads to the indication that
reduction or acetylation of carbonyl group at C-3 position will
abolish the activity. Also, the introduction of a hydrophilic
epoxy group will greatly diminish the activity. Moreover, com-
pound 39, the 20-oxime analog of progesterone, was less active
(IC50: 14 nM) than the corresponding carbonyl compound
(33). 1,4-Pregnadiene-20-oxime (40) exhibited inhibitory activ-
ity similar to that of compound (41) (IC50: 760 nM) and was
Figure 5 Some hemisynthetic and isolated natural compounds (6–23) along with their IC50 cytotoxic activity on human ﬁbrosarcoma
cell HT1080.
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Figure 6 Steroid 5a-reductase enzyme inhibitors (24–26).
Figure 7 C21 steroids (27–32); 5a-Reductase inhibitors.
Figure 8 Compounds 33–42.
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Figure 9 Cholesterol derivatives.
Figure 10 Cholesteryl 1,12-dicarba-closododecarborane 1-car-
boxylate (BCH).
10 A.A. Radwan, F.K. Alanazimore active than 6a,7a-epoxy-1,4-pregnadiene-20-one (42)
(IC50: >10000 nM) having an epoxy ring at the 6,7 position.
7. Cholesterol derivatives as DNA topoisomerase and cancer cell
growth inhibitor
The inhibitory activities of cholesterol derivatives (Fig. 9) such
as cholesterol, sodium cholesteryl sulfate, cholesteryl-5a, 6a-
epoxide, cholesteryl chloride, cholesteryl bromide, and cho-
lesteryl hemisuccinate (43–48,) against DNA polymerase
(pol), DNA topoisomerase (topo), and human cancer cell
growth were reported (Ishimaru et al., 2008). In the human
body, cholesterol derivatives cholesteryl sulfate (44) and cho-
lesteryl-5a, 6aepoxide (45) were produced by cholesterol sulfo-
transferase (Chida et al., 1995) and autoxidation (Ishimaru
et al., 2008), respectively. Compound 44 is a second messenger
of the g isoform of protein kinase C mediating squamous dif-
ferentiation, and inhibits the tumor promotional phase in
mouse skin carcinogenesis (Chida et al., 1995). Compound
44 is present at approximately 300 lg/100 ml (i.e., 6.1 l M) in
human body (Strott and Higashi, 2003), and this concentration
is almost the same inhibitory dose in pol/topo activities and
cancer cell growth. Since synthesized derivatives from choles-
terol in the body may have possible work in anti-cancer activ-
ity, a diet containing cholesterol prevents cancer disease.
Compounds 44 and 48 revealed themselves to be potent inhib-
itors of animal pols, and the IC50 values for pols were 0.84–
11.6 and 2.9–148 lM, respectively. Compounds 44, 45 and
48 inhibited the activity of human topo II, with IC50 values
of 5.0, 12.5 and 120 lM, respectively. Compounds 44, 45
and 48 also suppressed the human cancer cell (promyelocytic
leukemia cell line, HL-60) growth, and LD50 values were
8.8, 20.2 and 72.3 lM, respectively, suggesting that cell growth
inhibition had the same tendency as the inhibition of topos
rather than pols. Compounds 44 and 48 arrested the cells in
S and G2/M phases, compound 45 arrested the cells in the
G2/M phase, and these compounds also increased the sub-
G1phase in the cell cycle. These results suggested that the effect
of cell cycle arrest might be effective on both pol and topo
activities.
8. Cholesterol-induced antitumor synergism
Betulin (BE) which is a precursor of betulinic acid (BetA) is
isolated from different plants (Cichewicz and Kouzi, 2004).
It was found that BE induces apoptosis utilizing a similar
mechanism as BetA and is prevented by cyclosporin A
(CsA). In comparison with BetA, BE showed a more rapid
death, but achieves similar amounts of cell death at aconsiderably higher concentration. At the same time, it was
observed that cholesterol sensitized cells to BE-induced apop-
tosis, while there was no effect of cholesterol when combined
with BetA. Despite the signiﬁcantly enhanced cytotoxicity,
the mode of cell death was not changed as CsA completely
abrogated cell death. These ﬁndings indicate that BE has po-
tent anti-tumor activity especially in combination with choles-
terol (Mullauer et al., 2009).
Furthermore, cholesterol sequestration by nystatin, a poly-
ene antifungal drug, signiﬁcantly enhances endostatin uptake
by endothelial cells through the switching of endostatin inter-
nalization predominantly to the clathrin-mediated pathway.
Nystatin-enhanced internalization of endostatin also increases
its inhibitory effects on endothelial cell tube formation and
migration. More importantly this enhancement of the uptake
and therapeutic efﬁcacy of endostatin with cholesterol-seques-
tering agents selectively enhances endostatin uptake and bio-
distribution in tumor blood vessels and tumor tissues but not
in normal tissues of tumor-bearing mice, ultimately resulting
in elevated antiangiogenic and antitumor efﬁcacies of endo-
statin in vivo (Chen et al., 2011).
9. Cholesterol-based intracerebral delivery of chemotherapeutics
The lack of effective treatment options results in poor progno-
sis of brain tumor. It is crucial to deliver a sufﬁcient amount of
therapeutic agents to the brain tumor site. However, delivery
of therapeutic agents to the brain is technically challenging
due to the presence of blood brain barrier (BBB) (Zee-Cheng
and Cheng, 1989). Many attempts of special drug delivery have
been made to overcome this obstacle. One approach is to intra-
cerebrally administer the agents within brain parenchyma
through local delivery to tumor tissue (Lu et al., 1997). The
advantage of this approach is it results in high drug concentra-
tions at the tumor site with limited exposure to normal tissues
and organs. Another approach developed a cholesterol-
based anticancer agent containing carborane as the anticancer
unit for boron neutron capture therapy. The new com-
pound (Fig. 10), cholesteryl 1,12-dicarba-closo-dodecaborane
Figure 11 Schematic structure of cholesterol/Dox conjugates.
Figure 12 Chemical structure of folate-PEG-Cholesterol.
Targeting cancer using cholesterol conjugates 111-carboxylate (BCH) (49) mimics the native cholesteryl ester in
structure and was found to be effectively taken up by brain gli-
oma cells in vitro (Peacock et al., 2004). In addition, BCH was
formulated in liposomes and was administrated intracerebrally
to tumor-bearing rats. The ratio of BCH between tumor tissue
and normal tissue at 2, 6, 8, and 14 h were 5.46, 1.56, 1.12, and
1.01, respectively (Alanazi et al., 2004).
In a new approach, doxorubicin and cholesterol derivatives
(50) (Fig. 11) were bound by pH-sensitive hydrazone bonds to
N -(2-hydroxypropyl)methacrylamide (HPMA) copolymers.
At pH 5.0, the hydrazone bond showed a hydrolysis rate
strongly dependent on the microenvironment around thebond. This property led to the site-speciﬁc release of the doxo-
rubicin and hydrophobic domains because of the decrease in
pH in the endosomes or lysosomes of tumor cells. Doxorubicin
would be released in the ﬁrst stage, whereas the polymer mac-
romolecule would be disintegrated very slowly into short frag-
ments that are small enough to be eliminated by glomerular
ﬁltration (Chytil et al., 2012).
10. Cholesterol-based targeted delivery of anticancer compounds
One of the successful chemotherapeutic approaches is the bor-
on neutron capture therapy (BNCT) that is currently used to
Figure 13 Synthetic scheme for Mal-PEG-Chol.
Figure 14 Covalent conjugation of Fab’ fragments to MPB-PE liposomes.
12 A.A. Radwan, F.K. Alanazitreat brain tumors such as glioblastoma multiforme (GBM)
and anaplastic astrocytomas (AA) (Barth, 2003; Zamenhof
et al., 2004; Barth et al., 2005). BNCT delivers boron-10 to
the tumor tissue followed by external radiation of low energy
(e.g., 0.025 keV) thermal neutron that results in ﬁssion reac-
tions which produce high linear energy transfer (LET) a-parti-
cles and recoiling 7Li nuclei (10B + 1nﬁ [11*B] ﬁ 4He
(a) + 7Li + 2.39 MeV), which are highly lethal to surround-
ing cells. It is crucial for efﬁcient BNCT to selectively deliver
a sufﬁcient amount of 10B (20 lg/g tumor) to tumor cells
(Vicente, 2006; Wu et al., 2006). Delivery of 10B containing
agents via liposomes conjugated to the anti-EGFR monoclo-
nal antibody (MAb) cetuximab (C225) and L8A4, which is di-
rectly against EGFRvIII is an attractive delivery approach for
BNCT, because of their high payload capacity (Barth et al.,
2002; Wu et al., 2006). These liposomes consist of cholesterol
anchored folate (folate-PEG-Chol) (51) in EGFR-folate recep-
tor targeted liposomes (Fig. 12) (Lee and Low, 1994; Guo
et al., 2000) or consist of cholesterol anchored MAb (MAb-
PEG-Chol) (53) in the preparation of immunoliposomes (55)
(Figs. 13 and 14) (Pan et al., 2007).11. Cholesterol-sugar conjugates as anticancer agents against
peritoneal dissemination of tumor cells
Peritoneal dissemination of cancer cells is a major form of
recurrence in patients with advanced stages of gastric, colorec-
tal, ovarian, and pancreatic cancers after curative resection of
tumors (Vogel and Kalthoff, 2001; Sugarbaker, 2005; Koppe
et al., 2006; de Bree et al., 2006; Yan et al., 2006). In this phe-
nomenon, tumor cells exfoliate from the tumors to the abdom-
inal cavity, adhere to the surface of the peritoneum to invade
the basement membrane, and, in particular, adhere to the
greater omentum and the mesenterium (Asao et al., 1994; Asao
et al., 1995; Okamura et al., 2000). In this process cell surface
glycoconjugates have an essential role. Chemically synthesized
sugars have been developed as anti-adhesion molecules against
the peritoneal dissemination of cancer cells (Asao et al., 1994;
Asao et al., 1995; Okamura et al., 2000). Basically, chemically
synthesized sugar-cholestanols with mono-, di-, and tri-saccha-
rides attached to cholestanol (56) showed a strong inhibiting
activity against the proliferation of colorectal and gastric can-
cer cells by inducing apoptotic cell death. Also, these sugar-
Figure 15 Chemical structure of sugar-cholestanols with mono-, di-, and tri-saccharides attached to cholestanol and their IC50 in lM
against colorectal cells.
Figure 16 Cholestanol-sugar structures and their 50% of cell
proliferation inhibition (CPI50, lM) of TE-2, TE-13 and CHEK-1
cells respectively.
Targeting cancer using cholesterol conjugates 13cholestanols were suggested to have clinical potential as a no-
vel anticancer agent based on their strong inhibiting activity
against peritoneal dissemination in a mouse model. In con-
trast, cholestanol without sugar moieties was totally ineffec-
tive. Furthermore, when cancer cells were exposed to
GlcNAcRb-cholestanol (R = () or b1–3Gal; Fig. 15) (56),
the compound was rapidly taken up via the lipid rafts/micro-
domains on the cell surface. The uptake of sugar-cholestanol
in mitochondria increased gradually and was followed by the
release of cytochrome c from mitochondria and the activation
of apoptotic signals through the mitochondrial pathway and
the caspase cascade, leading to apoptotic cell death, character-
ized by DNA ladder formation and nuclear fragmentation
(Shinji et al., 2008).
In recent work, chemically synthesized sugar-cholestanols
(57) (Fig. 16) were demonstrated to possess potential multi-tar-
get anticancer activity against human esophageal cell lines be-
cause they induced apoptotic cell death of esophageal cancer
cells through modulating the Bcl-2 family, caspase cascade,
PARP and VEGF-A (Ahmad et al., 2007).In summary, this review focused not only on the cholesterol
blood level during some types of cancer diseases but also on
the great beneﬁt of using cholesterol derivatives in diagnosis
and in the perioperative and postoperative chemotherapy for
the treatment of various types of cancer diseases.
12. Future prospective
Conjugation of the cholesterol moiety to active medicinal com-
pounds for either cancer disease diagnosis or treatment is an
attractive approach for targeted drug delivery. There are many
additional areas in which this targeting tactic could be applied
to improve the chemotherapeutic efﬁcacy and to reduce the
toxicity to normal cells. For example, brain drug delivery pre-
sents a challenge due to the presence of blood brain barrier
(BBB). Several anticancer agents were victorised by cholesterol
for brain delivery and the experimental results appeared
promising.
It is well known that LDL receptors are present on the BBB
capillary endothelial cells and, therefore, they could be utilized
for transporting cholesteryl-based or other compounds to the
brain. Furthermore, cholesterol accumulates in the ovarian tissue
and is used to synthesize sex hormones. Therefore, cholesteryl drug
conjugates could also be used for drugs targeted to the ovary.
Since most of the cholesteryl drug conjugates are very
hydrophobic, suitable pharmaceutical formulations are also
required to enhance the solubility of these conjugates in blood
circulation and to improve their interactions with lipoproteins
and other functional proteins. Risks from the reaching of cho-
lesteryl conjugates to non-target tissues and cells need to be
investigated to fully assess the risk/beneﬁt ratio. Since the liver
most likely takes up signiﬁcant amount of these cholesteryl
conjugates, the associated pharmacological and toxic effects
should be speciﬁcally examined. Literature data have indicated
that local excess of cholesterol, the metabolic product of cho-
lesteryl conjugates, can be cytotoxic due to the build-up of free
cholesterol hydrolysate in the plasma membrane.
14 A.A. Radwan, F.K. AlanaziThe information related to biodistribution and pharmacoki-
netics of various cholesteryl drug conjugates is also essential for
their practical use. When active drug molecules are conjugated
to cholesterol, their properties, such as hydrophilicity/lipophil-
icity and molecular weight, are largely altered and consequently
their biodistribution, pharmacokinetics as well as efﬁcacy are
signiﬁcantly affected. Therefore, the delivery mechanism of
these new cholesteryl conjugates at cellular and molecular levels
involving their interactions with proteins, cells, receptors and
membranes becomes important and requires extensive investi-
gation. Nevertheless, utilization of cholesteryl drug conjugates
for targeted delivery provides a novel approach which has the
potential to enhance their therapeutic efﬁcacy and beneﬁt the
medical treatment of various human diseases.Acknowledgements
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